Alx Oncology Holdings Inc financial data

Symbol
ALXO on Nasdaq
Location
323 Allerton Avenue, South San Francisco, CA
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2025 - Aug 12, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 541 % +5.85%
Debt-to-equity 36.4 % +19.3%
Return On Equity -116 % -15%
Return On Assets -84.8 % -10.1%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 53.6M shares +1.67%
Common Stock, Shares, Outstanding 53.5M shares +2.01%
Entity Public Float 251M USD +55.6%
Common Stock, Value, Issued 54K USD +3.85%
Weighted Average Number of Shares Outstanding, Basic 53.4M shares +3.12%
Weighted Average Number of Shares Outstanding, Diluted 53.4M shares +3.12%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 91.9M USD -40.3%
General and Administrative Expense 26.6M USD -0.39%
Operating Income (Loss) -122M USD +32.6%
Net Income (Loss) Attributable to Parent -117M USD +32%
Earnings Per Share, Basic -2 USD/shares +39.9%
Earnings Per Share, Diluted -2 USD/shares +39.9%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 19.3M USD +24.3%
Other Assets, Current 4K USD -98.7%
Assets, Current 85.3M USD -49.5%
Property, Plant and Equipment, Net 1.5M USD -54.9%
Operating Lease, Right-of-Use Asset 1.45M USD -67.3%
Other Assets, Noncurrent 4.33M USD -67%
Assets 95.3M USD -55.6%
Accounts Payable, Current 4.9M USD -39.8%
Employee-related Liabilities, Current 2.79M USD -27.9%
Liabilities, Current 18.8M USD -51%
Operating Lease, Liability, Noncurrent 2.95M USD -25.4%
Other Liabilities, Noncurrent 5.06M USD -28.6%
Liabilities 30.9M USD -44.1%
Accumulated Other Comprehensive Income (Loss), Net of Tax 36K USD
Retained Earnings (Accumulated Deficit) -678M USD -20.8%
Stockholders' Equity Attributable to Parent 64.4M USD -59.6%
Liabilities and Equity 95.3M USD -55.6%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -24.7M USD +35%
Net Cash Provided by (Used in) Financing Activities 65K USD -97.9%
Net Cash Provided by (Used in) Investing Activities 27.6M USD +4.43%
Common Stock, Shares Authorized 1B shares 0%
Common Stock, Shares, Issued 53.5M shares +2.01%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 19.4M USD +24.2%
Deferred Tax Assets, Valuation Allowance 129M USD +34.4%
Operating Lease, Liability 3.95M USD -18.5%
Payments to Acquire Property, Plant, and Equipment 60K USD -59.5%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -116M USD +32%
Lessee, Operating Lease, Liability, to be Paid 4.83M USD -21%
Property, Plant and Equipment, Gross 3.17M USD -36.3%
Operating Lease, Liability, Current 1M USD +11.8%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 875K USD -30.8%
Deferred Tax Assets, Operating Loss Carryforwards 41.1M USD +55%
Unrecognized Tax Benefits 4.11M USD +31.7%
Operating Lease, Payments 322K USD +2.88%
Depreciation, Depletion and Amortization 211K USD -1.4%
Deferred Tax Assets, Net of Valuation Allowance 131M USD +33.6%
Share-based Payment Arrangement, Expense 20.2M USD -27.9%
Interest Expense 1.68M USD +1.32%